113 related articles for article (PubMed ID: 3134000)
41. Resolution of experimental intravitreal fibrin by tissue plasminogen activator.
Min WK; Kim YB
Korean J Ophthalmol; 1990 Dec; 4(2):58-65. PubMed ID: 2128708
[TBL] [Abstract][Full Text] [Related]
42. Clearance of intravitreal 3H-fluorouracil.
Case JL; Peyman GA; Barrada A; Hendricks R; Fiscella R; Hindi M
Ophthalmic Surg; 1985 Jun; 16(6):378-81. PubMed ID: 4022559
[TBL] [Abstract][Full Text] [Related]
43. Postoperative fluctuations of tissue plasminogen activator (t-PA) in aqueous humor of pseudophakes.
Yoshitomi F; Utsumi E; Hayashi M; Futenma M; Yamada R; Yamada S
J Cataract Refract Surg; 1991 Sep; 17(5):543-6. PubMed ID: 1941585
[TBL] [Abstract][Full Text] [Related]
44. Binding of 131I-labeled tissue-type plasminogen activator on de-endothelialized lesions in rabbits.
Uehara A; Isaka Y; Etani H; Kimura K; Yoneda S; Kamada T; Kozuka T; Nobuhara M
Nuklearmedizin; 1987 Oct; 26(5):224-8. PubMed ID: 3124079
[TBL] [Abstract][Full Text] [Related]
45. A spectrophotometric solid-phase fibrin-tissue plasminogen activator activity assay (SOFIA-tPA) for high-fibrin-affinity tissue plasminogen activators.
Angles-Cano E
Anal Biochem; 1986 Mar; 153(2):201-10. PubMed ID: 3085533
[TBL] [Abstract][Full Text] [Related]
46. Clearance of intravitreal voriconazole.
Shen YC; Wang MY; Wang CY; Tsai TC; Tsai HY; Lee YF; Wei LC
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2238-41. PubMed ID: 17460285
[TBL] [Abstract][Full Text] [Related]
47. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Lucore CL; Fujii S; Sobel BE
Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
[TBL] [Abstract][Full Text] [Related]
48. Intraocular injection of ceftazidime. Effects of inflammation and surgery.
Shaarawy A; Meredith TA; Kincaid M; Dick J; Aguilar E; Ritchie DJ; Reichley RM
Retina; 1995; 15(5):433-8. PubMed ID: 8594638
[TBL] [Abstract][Full Text] [Related]
49. Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes.
Jarus G; Blumenkranz M; Hernandez E; Sossi N
Ophthalmology; 1985 Jan; 92(1):91-6. PubMed ID: 3974999
[TBL] [Abstract][Full Text] [Related]
50. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
Masson C; Angles-Cano E
Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
[TBL] [Abstract][Full Text] [Related]
51. Use of tissue plasminogen activator for intraocular fibrinolysis in dogs.
Gerding PA; Essex-Sorlie D; Vasaune S; Yack R
Am J Vet Res; 1992 Jun; 53(6):894-6. PubMed ID: 1626779
[TBL] [Abstract][Full Text] [Related]
52. [Functional characterization of a monoclonal antibody which interferes with the binding of t-PA to fibrin].
Orbe J; Montes R; Chordá C; Páramo JA; Rocha E
Sangre (Barc); 1994 Aug; 39(4):261-6. PubMed ID: 7985055
[TBL] [Abstract][Full Text] [Related]
53. [Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation].
Xie L; Li S; Dong X; Cao J; Shi W; Guo P
Zhonghua Yan Ke Za Zhi; 1998 Jul; 34(4):291-3. PubMed ID: 11877211
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys.
Barza M; Kane A; Baum J
Invest Ophthalmol Vis Sci; 1983 Dec; 24(12):1602-6. PubMed ID: 6654640
[TBL] [Abstract][Full Text] [Related]
55. Design of a novel chimeric tissue plasminogen activator with favorable Vampire bat plasminogen activator properties.
Kazemali M; Majidzadeh-A K; Sardari S; Saadatirad AH; Khalaj V; Zarei N; Barkhordari F; Adeli A; Mahboudi F
Enzyme Microb Technol; 2014 Dec; 67():82-6. PubMed ID: 25442953
[TBL] [Abstract][Full Text] [Related]
56. Detecting endotoxin contamination of ophthalmic viscosurgical devices: intracameral versus intravitreal assays in rabbits.
Buchen SY; Calogero D; Hilmantel G; Eydelman MB
Ophthalmology; 2012 Jul; 119(7):e11-8. PubMed ID: 22578451
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes.
Gupta SK; Velpandian T; Dhingra N; Jaiswal J
J Ocul Pharmacol Ther; 2000 Dec; 16(6):511-8. PubMed ID: 11132898
[TBL] [Abstract][Full Text] [Related]
58. Increased basal levels of free plasminogen activator activity found in human aqueous humor.
Wang Y; Taylor DM; Smalley DM; Cone RE; O'Rourke J
Invest Ophthalmol Vis Sci; 1994 Aug; 35(9):3561-6. PubMed ID: 8056534
[TBL] [Abstract][Full Text] [Related]
59. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
Colucci M; Paramo JA; Stassen JM; Collen D
J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
[TBL] [Abstract][Full Text] [Related]
60. Technetium-99m-labeled recombinant tissue plasminogen activator for the imaging of emboli in vivo.
Takahashi A; Itoh K; Tsukamoto E; Furudate M; Kamiyama H; Abe H
Neurol Med Chir (Tokyo); 1993 Jul; 33(7):415-9. PubMed ID: 7692316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
